Quarterly ResultMay 27, 2026, 07:26 AM
BioLineRx Q1 Net Loss $2.6M; GLIX1 Phase 1/2a Trial Initiated
AI Summary
BioLineRx Ltd. reported its first quarter 2026 financial results, with a net loss of $2.6 million, a decrease from a net income of $5.1 million in the prior year. Revenues increased to $0.5 million, primarily from APHEXDA royalties. The company announced a significant milestone with the dosing of the first patient in its Phase 1/2a clinical trial of GLIX1 for glioblastoma (GBM) and presented encouraging new preclinical data for GLIX1. BioLineRx also confirmed its cash runway into the first half of 2027 with $17.4 million in cash and equivalents.
Key Highlights
- BioLineRx reported a net loss of $2.6 million for Q1 2026, compared to a net income of $5.1 million in Q1 2025.
- Revenues for Q1 2026 increased to $0.5 million from $0.3 million in Q1 2025, driven by APHEXDA royalties.
- Cash, cash equivalents, and short-term bank deposits totaled $17.4 million as of March 31, 2026.
- The company maintains its cash runway guidance into the first half of 2027.
- GLIX1 Phase 1/2a clinical trial for glioblastoma (GBM) was initiated in March 2026, with the first patient dosed.
- New GLIX1 preclinical data showed potent anti-tumor effects in GBM, including TMZ-resistant models.
- APHEXDA sales for Q1 2026 were $2.7 million, generating $0.5 million in royalty revenues.
- Research and development expenses increased by 55.8% to $2.5 million in Q1 2026, primarily due to the GLIX1 project.
Price Impact
More from BLRX